Article Text

PDF
Letter
Comment on ‘Predicting the response to infliximab from trough serum levels’
  1. K Bendtzen1,
  2. C Steenholdt2,
  3. M Ainsworth2,
  4. O Ø Thomsen2,
  5. J Brynskov2
  1. 1Institute for Inflammation Research, Copenhagen University Hospital Rigshospitalet, and BioMonitor A/S, Copenhagen, Denmark
  2. 2Department of Medical Gastroenterology, Copenhagen University Hospital, Herlev, Denmark
  1. Correspondence to Dr K Bendtzen, Institute for Inflammation Research, IIR7521, Rigshospitalet University Hospital, Copenhagen 2100, Denmark; kben{at}dbmail.dk

Statistics from Altmetric.com

We read with great interest the commentary by Rutgeerts et al1 on the value of predicting patient responses from trough serum levels of monoclonal antibodies (mAbs) against tumour necrosis factor-α (TNF). In fact, we have proposed therapeutic monitoring for rational use of anti-TNF mAb for quite some time.2

The authors point to the importance of low drug trough levels and ask how this can be explained in the absence of anti-drug antibodies (ADAs). They also pose the question whether ADAs are not always detected by routine assays. From experience with anti-TNF-treated patients with rheumatoid arthritis (RA) and Crohn's disease (CD), we can say that standard solid-phase assays (ELISAs) often fail to detect ADA because of high background values, matrix effects, for example epitope masking, and inability to detect ADA in the presence of the drug itself. Furthermore, …

View Full Text

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Linked Articles

  • PostScript
    Ann Gils Séverine Vermeire Gert Van Assche Paul Rutgeerts